Of course the ChatGPT dog cancer vaccine spawned a startup

Australian entrepreneur Paul Conyngham has launched Gamgee, a new biotech startup that aims to develop personalized mRNA cancer vaccines for dogs, with plans to eventually expand the treatment to humans and other species.

The company's inception follows a widely publicized social media story where Conyngham claimed to have used generative AI tools, including ChatGPT and Grok, alongside computational genomics to design a successful cancer treatment for his own dog, Rosie. Backed by the prominent startup accelerator Y Combinator, Gamgee is currently preparing for its initial clinical trials in Australia and has opened a global waitlist for pet owners seeking alternative treatments for their animals' tumors.

However, the scientific validity of the original case study has faced significant skepticism from veterinary and medical researchers. Experts have pointed out that because the entrepreneur's dog received the experimental mRNA vaccine concurrently with other standard cancer therapies, it is scientifically impossible to isolate the vaccine as the sole cause of her tumor reduction. Critics also argue that the narrative overstates the capability of existing artificial intelligence models in complex medical design while undermining the crucial role of human medical professionals. Despite these unresolved scientific questions, Gamgee continues to actively recruit veterinary partners and seek external funding, promising rapid vaccine development turnaround times based on its single initial case study.